Long-term safety and efficacy of tocilizumab (an anti-IL-6 receptor monoclonal antibody) in monotherapy, in patients with rheumatoid arthritis

被引：0
|
作者：
Nishimoto, N. [1 ]
Miyasaka, N. [2 ]
Yamamoto, K. [3 ]
Kawai, S. [4 ]
Takeuchi, T. [5 ]
Azuma, J. [6 ]
Kishimoto, T. [7 ]
机构：
[1] Osaka Univ, Grad Sch Frontier Biosci, Immune Lab Regulat, Suita, Osaka, Japan
[2] Tokyo Med & Dent Univ, Dept Med Rheumatol, Tokyo, Japan
[3] Univ Tokyo, Sch Med, Dept Allergy & Rheumatol, Tokyo, Japan
[4] Toho Univ, Omori Med Ctr, Div Rheumatol, Tokyo, Japan
[5] Saitama Med Ctr, Saitama Med Sch, Dept Rheumatol & Clin Immunol, Kawagoe, Saitama, Japan
[6] Osaka Univ, Grad Sch Pharmaceut Sci, Dept Clin Evaluat Med & Therapeut, Suita, Osaka 565, Japan
[7] Osaka Univ, Grad Sch Frontier Biosci, Lab Immune Regulat, Osaka, Japan
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：122 / 122
页数：1
相关论文
共 50 条
  • [21] How does anti-IL-6 receptor monoclonal antibody tocilizumab treatment ameliorate neuromyelitis optica?
    Matsuoka, T.
    Araki, M.
    Yamaguchi, H.
    Sato, W.
    Miyamoto, K.
    Kusunoki, S.
    Gold, R.
    Yamamura, T.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 1000 - 1001
  • [22] Long-Term Efficacy and Safety Results of a Global Phase 3 Trial of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment
    Thorne, Carter
    Takeuchi, Tsutomu
    Karpouzas, George
    Sheng, Shihong
    Kurrasch, Regina
    Fei, Kaiyin
    Hsu, Benjamin
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [23] The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab
    Sagawa, Akira
    MODERN RHEUMATOLOGY, 2011, 21 (04) : 352 - 358
  • [24] ANTI-IL-6 RECEPTOR ANTIBODY (TOCILIZUMAB): A B CELL TARGETING THERAPY
    Snir, A.
    Kessel, A.
    Haj, T.
    Rosner, I
    Rozenbaum, M.
    Slobodin, G.
    Toubi, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2011, 70
  • [25] ANTI-IL-6 RECEPTOR ANTIBODY (TOCILIZUMAB): A B CELL TARGETING THERAPY
    Toubi, E.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (01) : 152 - 152
  • [26] Long-Term Efficacy of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Previously Methotrexate Naive or Methotrexate Free for 6 Months.
    Jones, Graeme
    Sebba, Anthony
    Lepley, Denise
    Devenport, Jenny
    Bernasconi, Corrado
    Smart, Devi
    Mpofu, Chiedzo
    Gomez-Reino, Juan J.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S197 - S197
  • [27] Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy
    Snir, A.
    Kessel, A.
    Haj, T.
    Rosner, I.
    Slobodin, G.
    Toubi, E.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (04) : 697 - 700
  • [28] Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab
    Araki, Manabu
    Aranami, Toshimasa
    Matsuoka, Takako
    Nakamura, Masakazu
    Miyake, Sachiko
    Yamamura, Takashi
    MODERN RHEUMATOLOGY, 2013, 23 (04) : 827 - 831
  • [29] LONG-TERM SAFETY OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS (RA) PATIENTS (PTS)
    van Vollenhoven, Ronald
    Scali, Juan
    Curtis, Jeffrey R.
    Krasnow, Joel
    Vernon, Emma
    Alten, Rieke
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (09): : 1087 - 1087
  • [30] Anti-IL-6 receptor monoclonal antibody as a new treatment of endometriosis
    El-Zayadi, Ahmed A.
    Mohamed, Sara A.
    Arafa, Mohammad
    Mohammed, Shereen M.
    Zayed, Abdelhady
    Abdelhafez, Mohamed S.
    Badawy, Ahmed M.
    IMMUNOLOGIC RESEARCH, 2020, 68 (06) : 389 - 397
12345